Julie Patterson, John Michael O'Brien, Jonathan D Campbell
{"title":"肿瘤药物加速审批计划：庆祝超过 25 万个生命年的增长。","authors":"Julie Patterson, John Michael O'Brien, Jonathan D Campbell","doi":"10.37765/ajmc.2024.89590","DOIUrl":null,"url":null,"abstract":"<p><p>This commentary explores how 2 recently published studies evaluating the clinical benefit of the FDA's accelerated approval program for oncology drugs came to different conclusions.</p>","PeriodicalId":50808,"journal":{"name":"American Journal of Managed Care","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The accelerated approval program for oncology drugs: celebrating more than 250,000 life-years gained and counting.\",\"authors\":\"Julie Patterson, John Michael O'Brien, Jonathan D Campbell\",\"doi\":\"10.37765/ajmc.2024.89590\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>This commentary explores how 2 recently published studies evaluating the clinical benefit of the FDA's accelerated approval program for oncology drugs came to different conclusions.</p>\",\"PeriodicalId\":50808,\"journal\":{\"name\":\"American Journal of Managed Care\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2024-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American Journal of Managed Care\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.37765/ajmc.2024.89590\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"HEALTH CARE SCIENCES & SERVICES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Managed Care","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.37765/ajmc.2024.89590","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
The accelerated approval program for oncology drugs: celebrating more than 250,000 life-years gained and counting.
This commentary explores how 2 recently published studies evaluating the clinical benefit of the FDA's accelerated approval program for oncology drugs came to different conclusions.
期刊介绍：
The American Journal of Managed Care is an independent, peer-reviewed publication dedicated to disseminating clinical information to managed care physicians, clinical decision makers, and other healthcare professionals. Its aim is to stimulate scientific communication in the ever-evolving field of managed care. The American Journal of Managed Care addresses a broad range of issues relevant to clinical decision making in a cost-constrained environment and examines the impact of clinical, management, and policy interventions and programs on healthcare and economic outcomes.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
